Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Number of users of heart medication in Sweden 2018, by type and gender

Number of users of heart medication in Sweden in 2018, by type and gender

by F. Norrestad, last edited Apr 25, 2019
Number of users of heart medication in Sweden 2018, by type and gender This statistic shows the number of users of heart medication in Sweden in 2018, by type and gender. The most commonly used heart medication, among both men and women, were agents acting on the renin-angiotensin system. The number male users amounted to around 743 thousand, and the number of female users to around 649 thousand.
Show more

Number of users of heart medication in Sweden in 2018, by type and gender

Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Cardiovascular disease in Sweden "
  • Overview
The most important statistics
  • Treatment and care
  • Pacemaker
  • Heart attacks
  • Heart transplant
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.